These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Court refuses to hurry generic Lipitor decision. Harrison C Nat Rev Drug Discov; 2011 Jun; 10(6):406-7. PubMed ID: 21629283 [No Abstract] [Full Text] [Related]
6. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)]. März W MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673 [No Abstract] [Full Text] [Related]
7. The war over Lipitor. Eban K Fortune; 2011 May; 163(7):204-8, 210. PubMed ID: 21714441 [No Abstract] [Full Text] [Related]
8. Statin face-off. Surprises from the first head-to-head comparison. Gupta S Time; 2003 Nov; 162(21):83. PubMed ID: 14666603 [No Abstract] [Full Text] [Related]
9. Patent cliff. Billions to be saved--starting now. Lipitor led the way, and other blockbusters are following. Manag Care; 2011 Nov; 20(11):65. PubMed ID: 22175110 [No Abstract] [Full Text] [Related]
10. Concurrent use of clopidogrel (Plavix) and atorvasatin (Lipitor) is contraindicated. Chetty N; Naran NH; Munster M S Afr Med J; 2006 Apr; 96(4):264. PubMed ID: 16670787 [No Abstract] [Full Text] [Related]
11. Potential neurological value of statins increases. Bonetta L Nat Med; 2002 Jun; 8(6):541. PubMed ID: 12042786 [No Abstract] [Full Text] [Related]
12. Atorvastatin: a new agent for hyperlipidemia. Kupecz D Nurse Pract; 1997 Nov; 22(11):87-8, 90, 93. PubMed ID: 9403876 [No Abstract] [Full Text] [Related]
13. Torcetrapib and atorvastatin--should marketing drive the research agenda? Avorn J N Engl J Med; 2005 Jun; 352(25):2573-6. PubMed ID: 15972861 [No Abstract] [Full Text] [Related]
14. Benefits of atorvastatin in cholesterol lowering. Farmer JA Curr Atheroscler Rep; 2003 Mar; 5(2):94-5. PubMed ID: 12573192 [No Abstract] [Full Text] [Related]
15. Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease. Kiberd BA Nat Clin Pract Nephrol; 2006 Jul; 2(7):354-5. PubMed ID: 16932460 [No Abstract] [Full Text] [Related]
16. Formulary conversion programs: the need for patient-specific risk assessment. Singh S; Shrivastava R; Das V MedGenMed; 2004 Sep; 6(3):28. PubMed ID: 15520652 [No Abstract] [Full Text] [Related]
17. Statins for high-risk patients without heart disease or high cholesterol. Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400 [No Abstract] [Full Text] [Related]
18. [How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition]. MMW Fortschr Med; 2005 Nov; 147(45):54. PubMed ID: 16320655 [No Abstract] [Full Text] [Related]
19. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Mullins CD; Rattinger GB; Kuznik A; Koren MJ Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915 [TBL] [Abstract][Full Text] [Related]